Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

961
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
961
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

849
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
849
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

891
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
891
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Concluding remarks of the President].

Anales de la Real Academia Nacional de Medicina·2013
Same author

[Gastroesophageal reflux disease in obesity].

Anales de la Real Academia Nacional de Medicina·2013
Same author

[Innovations in defered emergency surgery for complete rupture of the membranous uretra].

Anales de la Real Academia Nacional de Medicina·2012
Same author

[Precept speech].

Anales de la Real Academia Nacional de Medicina·2012
Same author

[Reception and signal transduction implied in the differentiation of stem cells from human bone marrow until adipocytes].

Anales de la Real Academia Nacional de Medicina·2012
Same author

[Thoracic pain. A source of new knowledge].

Anales de la Real Academia Nacional de Medicina·2010

Related Experiment Video

Updated: Mar 18, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K

[IRRITABLE BOWEL SYNDROME. NEW HORIZONS].

Manuel Díaz-Rubio García

    Anales De La Real Academia Nacional De Medicina
    |July 13, 2016
    PubMed
    Summary

    Irritable bowel syndrome (IBS) is a chronic disorder influenced by gut microbiota changes. Understanding host-microbiota interactions offers new therapeutic avenues for IBS management.

    Area of Science:

    • Gastroenterology and Microbiology
    • Focuses on the gut microbiota and its role in chronic disorders.

    Context:

    • Irritable bowel syndrome (IBS) is a complex chronic condition.
    • Factors like infections, antibiotic use, and bowel cleansing can alter gut microbiota composition.
    • The intricate relationship between the host, microbiota, immune system, and enteric nervous system is crucial for IBS pathophysiology but not fully understood.

    Purpose:

    • To explore the significance of host-microbiota interactions in understanding IBS pathogenesis.
    • To identify potential therapeutic strategies for modulating the gut microbiota in IBS patients.

    Summary:

    • Investigates the complex origins of irritable bowel syndrome (IBS), highlighting the impact of factors affecting gut microbiota.
    • Emphasizes the importance of understanding host-microbiota interactions for elucidating IBS pathogenesis.

    More Related Videos

    Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
    06:01

    Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

    Published on: July 26, 2024

    1.1K
    Investigating Intestinal Inflammation in DSS-induced Model of IBD
    08:43

    Investigating Intestinal Inflammation in DSS-induced Model of IBD

    Published on: February 1, 2012

    69.2K

    Related Experiment Videos

    Last Updated: Mar 18, 2026

    Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
    10:37

    Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

    Published on: November 30, 2016

    8.7K
    Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
    06:01

    Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

    Published on: July 26, 2024

    1.1K
    Investigating Intestinal Inflammation in DSS-induced Model of IBD
    08:43

    Investigating Intestinal Inflammation in DSS-induced Model of IBD

    Published on: February 1, 2012

    69.2K
  • Discusses emerging therapeutic options including prebiotics, probiotics, novel analgesics, antibiotics like rifaximin, and fecal microbiota transplantation.

    • Impact:

    • Advances the understanding of gut microbiota's role in gastrointestinal disorders.
    • Suggests novel therapeutic strategies for irritable bowel syndrome (IBS) management.
    • Highlights fecal microbiota transplantation as a potential future treatment for IBS.